drugset
drugset / Trial / NCT00432185

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

NCT00432185 ↗

Phase 2 Completed 117 enrolled Peplin
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine maximum tolerated dose level (MTD) of PEP005 Topical Gel for the treatment of superficial basal cell carcinoma on the trunk

Timeline

Start
2007-02
Primary completion
2010-03
Completion
2010-03

Publications

  • Results Gross K. Safety and efficacy of ingenol mebutate (PEP005) gel for topical treatment of superficial basal cell carcinoma. J Am Acad Dermatol 2009; 60(3, Suppl. 1): AB141; P2928
  • Results Gross K, Schmieder GJ, Tu J. Maximum Tolerated Dose and Safety of PEP005 (ingenol mebutate) Gel for Topical Treatment of Superficial Basal Cell Carcinoma. Summer Academy, American Academy of Dermatology meeting, Boston, MA, 2009. 2009: Poster no. 1902 (31 p.)

Drugs

EvaluationDrugModalityDoseRoute
Comparator ingenol mebutate Small molecule 0.25 % Topical

Indications

skin basal cell carcinoma